


# Mutational Signature


Percent of SNVs  
attributed to signature




Treatment

carboplatin  
paclitaxel  
liposomal doxorubicin  
gemcitabine  
cyclophosphamide  
topotecan  
cisplatin  
olaparib  
bevacizumab  
docetaxel  
nab-paclitaxel  
etoposide  
farletuzumab/placebo

Cisplatin *G. gallus*  
Cyclophosphamide *G. gallus*  
Etoposide *G. gallus*  
Cisplatin *C. Elegans*  
(1) Age  
(2) BRCA  
(3) BRCA  
(4) MMR  
(5) MMR  
(6) MMR  
(7) MMR  
(8) AID  
(9) AID  
(10) POLE  
(11) POLE  
(12) AID  
(13) AID  
(14) AID  
(15) AID  
(16) AID  
(17) AID  
(18) AID  
(19) AID  
(20) AID  
(21) AID  
(22) AID  
(23) AID  
(24) AID  
(25) MMR  
(26) MMR  
(27) MMR  
(28) MMR  
(29) Tobacco  
(30) Tobacco



Pre-treatment



Post-treatment unique